Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

Gianluigi Ferretti, Alessandra Fabi, Paolo Carlini, Paola Papaldo, Paola Cordiali Fei, Serena Di Cosimo, Nello Salesi, Diana Giannarelli, Andrea Alimonti, Barbara Di Cocco, Giovanna D'Agosto, Valentina Bordignon, Elisabetta Trento, Francesco Cognetti

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the modifications of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion. Experimental Design: Eighteen consecutive breast cancer patients with bone metastases were evaluated for circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), metalloproteinase 1 (MMP-1), metalloproteinase 2 (MMP-2), interleukins 1β, 6 and 8 (IL-1β, IL-6, IL-8), interferon γ, tumor necrosis factor α (TNF-α) and transforming growth factor β1 just before and 2 and 7 days after ZA infusion. Results: The MMP-2 basal value showed a statistically significant decrease 48 h after ZA (p = 0.01), being at 7 days higher than the day 2 value (p = 0.03). The VEGF basal value showed a statistically significant decrease 48 h after ZA infusion (p = 0.03), increasing above the basal level at 7 days (p = 0.07). The bFGF basal level almost significantly decreased 2 days after infusion (p = 0.06), being at 7 days higher than the basal value (p = 0.09). Comparing the day 2 values with basal ones, the linear regression model showed a significant positive correlation between IL-8 and bFGF (p = 0.02), IL-8 and TNF-α (p <0.0001), bFGF and TNF-α (p = 0.01), MMP-1 and TNF-α (p = 0.02). Conclusions: ZA could exert an antiangiogenic activity and inhibition of tumor cell bone invasiveness by a transient reduction of VEGF, bFGF and MMP-2 circulating levels after infusion.

Original languageEnglish
Pages (from-to)35-43
Number of pages9
JournalOncology
Volume69
Issue number1
DOIs
Publication statusPublished - Aug 2005

Fingerprint

zoledronic acid
Angiogenesis Inducing Agents
Metalloproteases
Fibroblast Growth Factor 2
Interleukin-8
Matrix Metalloproteinase 1
Breast Neoplasms
Cytokines
Vascular Endothelial Growth Factor A
Fibroblast Growth Factor 1
Interleukin-1
Linear Models
Interleukin-6
Bone and Bones
Transforming Growth Factors
Matrix Metalloproteinases
Intravenous Infusions
Interferons
Research Design
Tumor Necrosis Factor-alpha

Keywords

  • Acute-phase cytokines
  • Bone metastases
  • Matrix metalloproteinase 2
  • Vascular endothelial growth factor
  • Zoledronate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. / Ferretti, Gianluigi; Fabi, Alessandra; Carlini, Paolo; Papaldo, Paola; Fei, Paola Cordiali; Di Cosimo, Serena; Salesi, Nello; Giannarelli, Diana; Alimonti, Andrea; Di Cocco, Barbara; D'Agosto, Giovanna; Bordignon, Valentina; Trento, Elisabetta; Cognetti, Francesco.

In: Oncology, Vol. 69, No. 1, 08.2005, p. 35-43.

Research output: Contribution to journalArticle

Ferretti, Gianluigi ; Fabi, Alessandra ; Carlini, Paolo ; Papaldo, Paola ; Fei, Paola Cordiali ; Di Cosimo, Serena ; Salesi, Nello ; Giannarelli, Diana ; Alimonti, Andrea ; Di Cocco, Barbara ; D'Agosto, Giovanna ; Bordignon, Valentina ; Trento, Elisabetta ; Cognetti, Francesco. / Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. In: Oncology. 2005 ; Vol. 69, No. 1. pp. 35-43.
@article{864115f805ab4d0a9a1dc9baa46e8b54,
title = "Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients",
abstract = "Background: To evaluate the modifications of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion. Experimental Design: Eighteen consecutive breast cancer patients with bone metastases were evaluated for circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), metalloproteinase 1 (MMP-1), metalloproteinase 2 (MMP-2), interleukins 1β, 6 and 8 (IL-1β, IL-6, IL-8), interferon γ, tumor necrosis factor α (TNF-α) and transforming growth factor β1 just before and 2 and 7 days after ZA infusion. Results: The MMP-2 basal value showed a statistically significant decrease 48 h after ZA (p = 0.01), being at 7 days higher than the day 2 value (p = 0.03). The VEGF basal value showed a statistically significant decrease 48 h after ZA infusion (p = 0.03), increasing above the basal level at 7 days (p = 0.07). The bFGF basal level almost significantly decreased 2 days after infusion (p = 0.06), being at 7 days higher than the basal value (p = 0.09). Comparing the day 2 values with basal ones, the linear regression model showed a significant positive correlation between IL-8 and bFGF (p = 0.02), IL-8 and TNF-α (p <0.0001), bFGF and TNF-α (p = 0.01), MMP-1 and TNF-α (p = 0.02). Conclusions: ZA could exert an antiangiogenic activity and inhibition of tumor cell bone invasiveness by a transient reduction of VEGF, bFGF and MMP-2 circulating levels after infusion.",
keywords = "Acute-phase cytokines, Bone metastases, Matrix metalloproteinase 2, Vascular endothelial growth factor, Zoledronate",
author = "Gianluigi Ferretti and Alessandra Fabi and Paolo Carlini and Paola Papaldo and Fei, {Paola Cordiali} and {Di Cosimo}, Serena and Nello Salesi and Diana Giannarelli and Andrea Alimonti and {Di Cocco}, Barbara and Giovanna D'Agosto and Valentina Bordignon and Elisabetta Trento and Francesco Cognetti",
year = "2005",
month = "8",
doi = "10.1159/000087286",
language = "English",
volume = "69",
pages = "35--43",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

AU - Ferretti, Gianluigi

AU - Fabi, Alessandra

AU - Carlini, Paolo

AU - Papaldo, Paola

AU - Fei, Paola Cordiali

AU - Di Cosimo, Serena

AU - Salesi, Nello

AU - Giannarelli, Diana

AU - Alimonti, Andrea

AU - Di Cocco, Barbara

AU - D'Agosto, Giovanna

AU - Bordignon, Valentina

AU - Trento, Elisabetta

AU - Cognetti, Francesco

PY - 2005/8

Y1 - 2005/8

N2 - Background: To evaluate the modifications of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion. Experimental Design: Eighteen consecutive breast cancer patients with bone metastases were evaluated for circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), metalloproteinase 1 (MMP-1), metalloproteinase 2 (MMP-2), interleukins 1β, 6 and 8 (IL-1β, IL-6, IL-8), interferon γ, tumor necrosis factor α (TNF-α) and transforming growth factor β1 just before and 2 and 7 days after ZA infusion. Results: The MMP-2 basal value showed a statistically significant decrease 48 h after ZA (p = 0.01), being at 7 days higher than the day 2 value (p = 0.03). The VEGF basal value showed a statistically significant decrease 48 h after ZA infusion (p = 0.03), increasing above the basal level at 7 days (p = 0.07). The bFGF basal level almost significantly decreased 2 days after infusion (p = 0.06), being at 7 days higher than the basal value (p = 0.09). Comparing the day 2 values with basal ones, the linear regression model showed a significant positive correlation between IL-8 and bFGF (p = 0.02), IL-8 and TNF-α (p <0.0001), bFGF and TNF-α (p = 0.01), MMP-1 and TNF-α (p = 0.02). Conclusions: ZA could exert an antiangiogenic activity and inhibition of tumor cell bone invasiveness by a transient reduction of VEGF, bFGF and MMP-2 circulating levels after infusion.

AB - Background: To evaluate the modifications of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion. Experimental Design: Eighteen consecutive breast cancer patients with bone metastases were evaluated for circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), metalloproteinase 1 (MMP-1), metalloproteinase 2 (MMP-2), interleukins 1β, 6 and 8 (IL-1β, IL-6, IL-8), interferon γ, tumor necrosis factor α (TNF-α) and transforming growth factor β1 just before and 2 and 7 days after ZA infusion. Results: The MMP-2 basal value showed a statistically significant decrease 48 h after ZA (p = 0.01), being at 7 days higher than the day 2 value (p = 0.03). The VEGF basal value showed a statistically significant decrease 48 h after ZA infusion (p = 0.03), increasing above the basal level at 7 days (p = 0.07). The bFGF basal level almost significantly decreased 2 days after infusion (p = 0.06), being at 7 days higher than the basal value (p = 0.09). Comparing the day 2 values with basal ones, the linear regression model showed a significant positive correlation between IL-8 and bFGF (p = 0.02), IL-8 and TNF-α (p <0.0001), bFGF and TNF-α (p = 0.01), MMP-1 and TNF-α (p = 0.02). Conclusions: ZA could exert an antiangiogenic activity and inhibition of tumor cell bone invasiveness by a transient reduction of VEGF, bFGF and MMP-2 circulating levels after infusion.

KW - Acute-phase cytokines

KW - Bone metastases

KW - Matrix metalloproteinase 2

KW - Vascular endothelial growth factor

KW - Zoledronate

UR - http://www.scopus.com/inward/record.url?scp=23944446040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944446040&partnerID=8YFLogxK

U2 - 10.1159/000087286

DO - 10.1159/000087286

M3 - Article

C2 - 16088233

AN - SCOPUS:23944446040

VL - 69

SP - 35

EP - 43

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -